A Phase 1/2 Study Of Zn-C3 Plus Gemcitabine In Relapsed Or Refractory Osteosarcoma

A Phase 1/2 Study of ZN-c3 Plus Gemcitabine in Relapsed or Refractory Osteosarcoma

Osteosarcoma: MIB Agents Osteosarcoma Alliance

SELISARC: selinexor plus gemcitabine in leiomyosarcoma and osteosarcoma

Clinical Trial: ZN-c3 for Ovarian Cancer (NCT05198804)

Power Life Sciences

MAESTRO: Phase III Study of Evofosfamide (EVO) in Combination with Gemcitabine...

Osteosarcoma Education: MIB Agents

Osteosarcoma: MIB Agents Osteosarcoma Alliance

Clinical Utility of Functional Precision Medicine to Guide Treatments for Osteosarcoma Patients

Osteosarcoma: MIB Agents Osteosarcoma Alliance

Phase I study of CD123 NK cell engager SAR443579 in R/R AML, B-ALL or HR-MDS

VJHemOnc – Video Journal of Hematology & HemOnc

ESPAC-4: Phase III Trial of Combination Gemcitabine and Capecitabine vs. Gemcitabine...

Exploring the use of a Predictive Tool for Methotrexate Clearance

Osteosarcoma: MIB Agents Osteosarcoma Alliance

GAP study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer

Cell Pathology and Infection 2 part 2 staging

Panel: Clinical Trials

Osteosarcoma: MIB Agents Osteosarcoma Alliance

Preoperative management of operable cT3 cN1 luminal breast cancer: Upfront neoadjuvant chemotherapy

First-in-human phase 1 study of TAK-931 for solid tumours

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

ChemoMetec

European Society for Gene and Cell Therapy

Locally advanced GE junction cancer - Peri-operative CT

Borealis-1™: Phase 2 trial of gemcitabine/cisplatin plus apatorsen in advanced bladder cancer

EMJ